GeneHealth - Your precision medicine

Gestational Trophoblastic Tumour

Disease Details

Family Health Simplified

Buy Membership

Description: Gestational trophoblastic tumor is a rare group of pregnancy-related tumors that arise from abnormal growth of trophoblast cells, which are normally involved in embryo development and placental formation.
Type: Gestational trophoblastic tumor (GTT) is a type of gestational trophoblastic disease, which includes different forms such as hydatidiform mole (complete or partial), invasive mole, choriocarcinoma, and placental site trophoblastic tumor (PSTT).

There is no specific genetic transmission pattern associated with gestational trophoblastic tumors. However, certain genetic factors and abnormal fertilization events (such as the fertilization of an empty egg or duplication of paternal chromosomes) can contribute to their development.
Signs And Symptoms: Gestational trophoblastic tumors are a group of rare tumors that involve abnormal growth of cells inside a woman's uterus. Common signs and symptoms include:

- Vaginal bleeding not associated with menstruation
- Rapidly enlarging uterus, often more than expected for gestational age
- Severe nausea and vomiting
- High levels of hCG (human chorionic gonadotropin) in blood tests, which may lead to pregnancy-related symptoms
- Absent fetal heart tones when a molar pregnancy is present
- Pelvic pain or discomfort

These signs and symptoms can vary depending on the specific type of gestational trophoblastic disease.
Prognosis: Gestational trophoblastic tumors (GTT) generally have an excellent prognosis, especially when diagnosed and treated early. The prognosis largely depends on the specific type of tumor, the stage at diagnosis, and the patient's overall health. Nan refers to "not a number," which typically indicates missing or inapplicable data, and does not provide additional context for prognosis. Overall, with appropriate treatment, most patients with GTT can achieve a high cure rate.
Onset: Gestational trophoblastic tumor (GTT) typically occurs during or after pregnancy. The onset often happens within weeks to months following the conclusion of a pregnancy, which could be a normal delivery, miscarriage, or molar pregnancy. The exact timing can vary depending on the specific type of gestational trophoblastic disease involved. Early detection is crucial for effective management and treatment.
Prevalence: The prevalence of gestational trophoblastic tumors (GTTs) varies by region. In North America and Europe, they occur in about 1 in 1,000 pregnancies, while in Southeast Asia, the incidence is higher, ranging from 1 in 500 to 1 in 200 pregnancies.
Epidemiology: Gestational trophoblastic tumors (GTT) are rare conditions related to abnormal growth of cells inside a woman's uterus. The estimated incidence varies geographically, occurring in approximately 1 in 1,000 pregnancies in North America and Europe, but more frequently in Asia and Latin America. Most commonly observed in women of reproductive age, particularly those under 20 or over 40 years old, GTTs are more likely to arise from molar pregnancies or following a miscarriage or normal term pregnancy. Effective management and treatment have substantially improved outcomes, with most cases having a high cure rate after early detection and appropriate therapy.
Intractability: Gestational trophoblastic tumors (GTTs) are not considered intractable. These tumors, which include conditions like hydatidiform mole (molar pregnancy), invasive mole, choriocarcinoma, and placental-site trophoblastic tumor, generally have a high cure rate with appropriate treatment. The disease is typically highly sensitive to chemotherapy, and the prognosis is excellent in most cases, especially if diagnosed early and managed properly.
Disease Severity: Gestational trophoblastic tumors (GTTs) can vary in severity. The severity depends on the specific type of GTT, which includes hydatidiform mole (complete and partial), invasive mole, choriocarcinoma, and placental site trophoblastic tumor.

1. **Hydatidiform Mole (Partial or Complete)**:
- **Severity:** Generally considered less severe but requires monitoring because of the potential to develop into more aggressive forms.
- **Treatment:** Often removed surgically; followed by monitoring of hCG levels.

2. **Invasive Mole**:
- **Severity:** More severe than a hydatidiform mole due to its potential to invade the uterine wall.
- **Treatment:** Typically treatable with chemotherapy.

3. **Choriocarcinoma**:
- **Severity:** A highly malignant form that can spread rapidly to other organs.
- **Treatment:** Requires prompt chemotherapy, often effective but necessitates close follow-up.

4. **Placental Site Trophoblastic Tumor (PSTT)**:
- **Severity:** Rare and can be more resistant to chemotherapy; the prognosis depends on early detection.
- **Treatment:** Often involves surgery and possibly additional treatments depending on the stage.

Overall, GTTs can range from benign to highly malignant, making early diagnosis and appropriate treatment crucial for favorable outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:3590
Pathophysiology: Gestational trophoblastic tumor (GTT) is a group of rare tumors that involve abnormal growth of cells inside a woman's uterus. These tumors start in the trophoblast, the layer of cells that surrounds the embryo and eventually forms part of the placenta.

**Pathophysiology:**

GTTs arise from abnormal fertilization processes and are characterized by the proliferation of trophoblastic tissue, which can invade the uterine wall and, in some cases, metastasize. The most common forms of GTT are:

1. **Hydatidiform Mole (Molar Pregnancy):**
- **Complete Mole:** Occurs when an egg with no genetic material is fertilized by one or two sperm, resulting in a 46,XX or 46,XY karyotype with only paternal DNA. This leads to the growth of abnormal trophoblastic tissue without fetal tissue.
- **Partial Mole:** Happens when a normal egg is fertilized by two sperm, resulting in a triploid karyotype (69 chromosomes). This often includes some fetal tissue along with abnormal trophoblasts.

2. **Invasive Mole:** A molar pregnancy that invades the muscular layer of the uterus (myometrium). It can lead to severe bleeding and may metastasize.

3. **Choriocarcinoma:** A highly malignant form of GTT that can develop from any type of gestational event (normal pregnancy, abortion, molar pregnancy). It consists of anaplastic trophoblastic cells that invade and metastasize rapidly.

4. **Placental Site Trophoblastic Tumor (PSTT):** Arises from the intermediate trophoblast, which is part of the placenta. This form tends to grow more slowly but can still be invasive and metastasize.

In GTT, the abnormal trophoblastic tissue secretes high levels of human chorionic gonadotropin (hCG), which can be detected in the blood and serves as a marker for diagnosis and monitoring treatment response. The excess hCG may also contribute to symptoms such as hyperemesis gravidarum and ovarian cysts.

Understanding the pathophysiology of GTT is crucial for early diagnosis, appropriate treatment, and monitoring to prevent complications and ensure favorable outcomes.
Carrier Status: Gestational trophoblastic tumours are not typically associated with a carrier status because they are not inherited conditions. These tumours arise from abnormal growth of cells in the uterus following conception and are more often related to molar pregnancies or abnormalities in the fertilization process rather than genetic inheritance. Therefore, carrier status is not applicable to gestational trophoblastic tumours.
Mechanism: Gestational trophoblastic tumors (GTTs) are a group of rare tumors involving abnormal growth of cells inside a woman's uterus that would normally develop into the placenta during pregnancy. The mechanism and molecular mechanisms underlying these tumors primarily involve abnormal fertilization and genetic alterations.

### Mechanism
GTTs arise from the trophoblastic tissue, which is responsible for forming the placenta. These tumors can result from different types of abnormal fertilization events, such as:

1. **Complete Hydatidiform Mole (CHM)**: Occurs when an egg with no genetic material is fertilized by one (and then duplicates) or two sperm, leading to a completely paternal genome.
2. **Partial Hydatidiform Mole (PHM)**: Happens when a normal egg is fertilized by two sperm, resulting in a triploid genome (containing three sets of chromosomes).

### Molecular Mechanisms
Several molecular mechanisms have been identified in the pathogenesis of gestational trophoblastic tumors:

1. **Genomic Imprinting and Paternal Excess**: GTTs are often characterized by abnormal imprinting and paternal genomic excess. In CHMs, the entire genome is paternal, while in PHMs, there is an extra paternal set of chromosomes.

2. **Gene Mutations and Epigenetic Changes**: Specific gene mutations and epigenetic alterations can play a role.
- **p53 Pathway**: Alterations in the tumor suppressor gene TP53 and other components of its pathway can contribute.
- **Genomic Instability**: Aberrations in the DNA repair mechanisms can result in genomic instability, contributing to the formation of these tumors.

3. **Growth Factor Signaling**: Changes in growth factor signaling pathways, such as the Human Chorionic Gonadotropin (hCG) signaling, can be involved. hCG is often elevated in GTTs and contributes to trophoblastic proliferation.

4. **Immune Evasion**: GTTs may develop mechanisms to evade the immune system, ensuring their survival and proliferation despite the host's immune responses.

Understanding these mechanisms is crucial for diagnosis, management, and developing targeted therapies for gestational trophoblastic tumors.
Treatment: Gestational trophoblastic tumors (GTT) are a group of pregnancy-related tumors that include conditions like hydatidiform mole, invasive mole, choriocarcinoma, and placental-site trophoblastic tumor. Treatment generally depends on the specific type and extent of the disease:

1. **Hydatidiform Mole (Molar Pregnancy):**
- Suction curettage is the primary treatment to remove the molar tissue from the uterus.
- Follow-up involves monitoring human chorionic gonadotropin (hCG) levels to ensure they return to normal, indicating that no molar tissue remains.

2. **Persistent Gestational Trophoblastic Disease (residual trophoblastic tissue after molar pregnancy):**
- Chemotherapy is the main treatment, typically using methotrexate or actinomycin-D, depending on the patient’s risk factors and hCG levels.
- Additional surgical intervention, such as hysterectomy, may be considered in some cases.

3. **Choriocarcinoma:**
- This highly malignant type usually requires chemotherapy even if metastasis is not evident.
- Common chemotherapy regimens include EMA-CO (etoposide, methotrexate, actinomycin-D - cyclophosphamide, vincristine) for high-risk cases.
- Surgery or radiation therapy may be utilized for localized tumors or resistant disease areas.

4. **Placental-Site Trophoblastic Tumor (PSTT):**
- These are rarer and often less sensitive to chemotherapy.
- Surgery, particularly hysterectomy, is typically the treatment of choice.
- Chemotherapy may be considered in cases of metastatic disease or if surgery is not completely successful.

For all types of GTT, regular monitoring of hCG levels post-treatment is crucial to ensure the disease is effectively managed and to detect any recurrence early.
Compassionate Use Treatment: For gestational trophoblastic tumor (GTT), compassionate use treatment and off-label or experimental treatments may include:

1. **Targeted Therapies:** Drugs like sunitinib or imatinib, which are typically used for other cancers, might be considered on a compassionate use basis if standard treatments fail.

2. **Immunotherapy:** Agents such as pembrolizumab (Keytruda), which is approved for various cancers, are being explored for their potential effectiveness in treating GTT.

3. **Chemotherapeutic Agents:** Some chemotherapeutic drugs not specifically approved for GTT, such as paclitaxel or docetaxel, may be used off-label.

These treatments are typically considered when conventional therapy, like methotrexate or dactinomycin, proves ineffective.
Lifestyle Recommendations: For gestational trophoblastic tumor (GTT), there are no specific lifestyle recommendations to prevent the condition due to its unique nature and origin. However, once diagnosed and undergoing treatment, maintaining a healthy lifestyle can support overall well-being and recovery. Here are some general lifestyle recommendations for those undergoing treatment for GTT:

1. **Follow Medical Advice:** Strictly adhere to treatment plans and regular follow-up appointments as advised by your healthcare provider.

2. **Nutrition:** Eat a balanced diet rich in fruits, vegetables, lean proteins, and whole grains to support immune function and overall health.

3. **Hydration:** Stay well-hydrated by drinking plenty of water.

4. **Rest and Sleep:** Ensure adequate rest and proper sleep to help your body recover and cope with treatment side effects.

5. **Avoid Alcohol and Smoking:** Quit smoking and avoid alcohol as they can interfere with the effectiveness of treatment and overall health.

6. **Physical Activity:** Engage in moderate physical activity as advised by your doctor to help maintain strength and reduce fatigue.

7. **Support System:** Seek support from family, friends, or support groups to help manage emotional and psychological stress.

8. **Stress Management:** Practice stress-reducing techniques such as yoga, meditation, or deep-breathing exercises.

Always consult your healthcare provider before making any significant changes to your lifestyle, especially during treatment for gestational trophoblastic tumor.
Medication: Medications commonly used to treat gestational trophoblastic tumors include methotrexate and actinomycin-D. In cases of high-risk disease, EMA-CO (etoposide, methotrexate, and actinomycin-D, alternating with cyclophosphamide and vincristine) chemotherapy may be used. Treatment selection depends on the specific type and severity of the tumor and patient factors.
Repurposable Drugs: Repurposable drugs for gestational trophoblastic tumour include:

1. **Methotrexate**: Commonly used as the first-line treatment for low-risk gestational trophoblastic disease.
2. **Dactinomycin (Actinomycin D)**: Often used in cases where methotrexate is not effective or as part of combination therapy.
3. **Etoposide**: Used in combination regimens for high-risk disease.
4. **Cyclophosphamide**: Utilized in multi-drug regimens for more aggressive disease.
5. **Vincristine**: Part of combination chemotherapy protocols like EMA-CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine).

Research into other repurposable drugs is ongoing, and treatment protocols may evolve as new therapies are discovered.
Metabolites: Metabolites associated with gestational trophoblastic tumors (GTT) are typically elevated levels of human chorionic gonadotropin (hCG). This hormone can be measured in blood and urine tests and is an important marker for diagnosis, monitoring treatment response, and detecting possible relapse of the disease.
Nutraceuticals: There is currently no direct evidence supporting the use of nutraceuticals for the treatment or management of gestational trophoblastic tumors (GTT). Treatment typically involves chemotherapy, surgery, and careful monitoring of human chorionic gonadotropin (hCG) levels. Always consult with a healthcare specialist for appropriate diagnosis and treatment options for GTT.
Peptides: Regarding gestational trophoblastic tumor, information on specific peptides and their roles is limited but ongoing research explores their potential in diagnosis and treatment. Studies often investigate biomarkers like human chorionic gonadotropin (hCG) levels, which can correlate with tumor presence and progression. However, detailed insights into peptides in gestational trophoblastic disease are still under research and development.